Results 101 to 110 of about 5,890 (202)

Meta-analysis of studies directly comparing topical amphotericin B treatments and intralesional meglumine antimoniate.

Meta-analysis of studies directly comparing topical amphotericin B treatments and intralesional meglumine antimoniate.
Líndicy Leidicy Alves (14135881), Mariana Lourenço Freire (6996530), Eliane de Morais-Teixeira (18389754), Gláucia Cota (4679719), Isadora Lana Troian (18389751)   +4 more
core   +1 more source

Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum

, 2017
Leishmaniasis is a neglected tropical disease caused by >20 species of the protozoan parasite Leishmania . Meglumine antimoniate (Glucantime) is the first-choice drug recommended by the World Health Organization for the ...
Maria Norma Melo, Silma Regina Ferreira Pereira, Antonio Marcus de Andrade Paes, Bruno Araújo Serra Pinto, Luís Cláudio Lima de Jesus, Rossy-Eric Pereira Soares, Vanessa Ribeiro Moreira, Luis Douglas Miranda Silva   +7 more
core   +1 more source

Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate

Revista da Sociedade Brasileira de Medicina Tropical, 2005
We retrospectively analyzed a series of 151 cases of cutaneous leishmaniasis treated between 1967 and 1982. One-hundred-and-thirty-nine (92%) patients presented with active lesions and were treated with daily doses of meglumine antimoniate: 81 adults ...
Armando de Oliveira Schubach, Keyla B. Feldman Marzochi, João Soares Moreira, Tânia Maria Pacheco Schubach, Marcelo Lodi Araújo, Antônio Carlos Francesconi do Vale, Sonia Regina Lambert Passos, Mauro Célio de Almeida Marzochi   +7 more
doaj  

In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B

, 2010
Resistance of Leishmania parasites to specific chemotherapy has become a well-documented problem in the Indian subcontinent in recent years but only a few studies have focused on the susceptibility of American Leishmania isolates.
ZAULI-NASCIMENTO, Rogeria C., RIBEIRO-DIAS, Fatima, ULIANA, Silvia R. B., DORTA, Miriam L., YOKOYAMA-YASUNAKA, Jenicer K. U., PEREIRA, Ledice I. A., OLIVEIRA, Milton A. Pelli de, MIGUEL, Danilo C.   +7 more
core   +1 more source

A cross-sectional study on sociodemographic, clinical, and therapeutic characteristics of a pediatric population with cutaneous leishmaniasis

Asian Pacific Journal of Tropical Medicine
Objective: To characterize the pediatric population with cutaneous leishmaniasis treated at a research center and to determine the therapeutic response and safety of the treatment.
Susana Ríos-Echavarría, Juliana Quintero-Pulgarín, Claudia Beltrán, Liliana López-Carvajal   +3 more
doaj   +1 more source

Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis

Medical Journal of South Punjab
Objective: The study aims to compare the efficacy and safety of meglumine antimoniate and miltefosine in the treatment of cutaneous leishmaniasis in Pakistan. Methodology: This randomized-controlled trial was conducted at the Dermatology Departments of Pak Emirates Military Hospital Rawalpindi, Pakistan, from January to December 2021.
Saima Shahid, Aisha Akhter
openaire   +1 more source

Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.

, 1996
Few data are available concerning the genotoxic effects of antimonial salts therapy in humans. A patient suffering from visceral leishmaniasis was treated for 15 days with a cumulative dose meglumine antimoniate 42.5 g.
Hantson, Philippe, Delaere, Bénédicte, Léonard, Alain, Mahieu, Paul, Vandercam, Bernard, Crutzen-Fayt, Marie-Christine, Léonard, Eliane D.   +6 more
core  

Administration of miltefosine and meglumine antimoniate in healthy Beagle dogs: clinical and histopathological evaluation of the impact on the kidneys

, 2009
In canine leishmaniosis (CanL), kidneys are affected in virtually all dogs. Treatment of CanL is limited in Europe to meglumine antimoniate and miltefosine.
CAVICCHIOLI, LAURA, VISCHER C, VALENTE, MARIALUISA, GIROUD L, BROVIDA C, CASTAGNARO, MASSIMO, BIANCIARDI P, ARESU, LUCA   +7 more
core   +1 more source

Antileishmanial potentials of azacitidine and along with meglumine antimoniate on Leishmania major: In silico prediction and in vitro analysis. [PDF]

PLoS One, 2023
Derakhshani A, Sharifi I, Salarkia E, Keyhani A, Agha Kuchak Afshari S, Iranmanesh B, Lashkarizadeh M, Nejad Biglari H, Lari Najafi M, Bamorovat M.   +9 more
europepmc   +1 more source

Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: A retrospective study

, 2013
A retrospective study was performed using 53 client owned dogs with leishmaniasis to determine whether the degree of proteinuria, evaluated by the urine protein/creatinine ratio (UP/C), changes following treatment with meglumine antimoniate and ...
Roura X., Paltrinieri S., Poggi M., Zatelli A., Pierantozzi M.   +4 more
core   +1 more source